Sandoz Group AG

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
32.06 ^CHF	+1.04%		+0.12%	+18.48%

May. 22	Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	CF
May. 22	Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars	MT

SANDOZ : Raised to Buy by Berenberg

October 05, 2023 at 07:25 am EDT

Berenberg's analyst Victoria Lambert upgrades his rating from Neutral to Buy. The target price continues to be set at CHF 35.

Latest news about Sandoz Group AG

Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	May. 22	CF
Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars	May. 22	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	May. 08	MT
Swiss Market Index Closes Higher; Sandoz Gains	May. 08	MT
SANDOZ : Sandoz’s improvements are worth betting on	May. 08
SANDOZ : Q1 miss not a worry; expect another boost for the share price	May. 07
Sandoz: 5% sales growth in Q1	May. 07	CF
Transcript : Sandoz Group AG, Q1 2024 Sales/ Trading Statement Call, May 07, 2024	May. 07
Sandoz Group Logs Growth in Q1 Net Sales, Affirms FY24 Outlook	May. 07	MT
Sandoz Announces Sales Results for the First Quarter 2024	May. 07	CI
Sandoz Group Ag Reiterates Earnings Guidance for the Full Year 2024	May. 07	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
Sandoz Group AG Announces Appointment of Graeme Pitkethly as Non-Executive Director and Chair of Its Audit, Risk and Compliance Committee	Apr. 30	CI
Sandoz Group AG Announces Board and Committee Appointments	Apr. 30	CI
Sandoz Group AG Approves Dividend, Payable on May 7, 2024	Apr. 30	CI
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation	Apr. 30	DJ
Sandoz Group Settles Patent Disputes with Amgen	Apr. 30	MT
Sandoz reaches agreement with Amgen over patent dispute	Apr. 30	RE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25	RE
Swiss Market Index Closes Higher; UBS Slumps	Apr. 22	MT
Sandoz Upgrades Sandoz to Buy from Neutral, Boosts PT	Apr. 22	MT
Sandoz: boosted by broker upgrade	Apr. 22	CF
SANDOZ : UBS raises its recommendation	Apr. 22	CF

Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Companyâs product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.

Sector

Pharmaceuticals

Calendar

2024-06-10 - Stifel Swiss Equities Conference

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANDOZ : Sandoz’s improvements are worth betting on

May 08, 2024 at 08:08 am EDT

More Strategies

Ratings for Sandoz Group AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.48 USD

Average target price

39.82 USD

Spread / Average Target

+12.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SANDOZ GROUP AG	+18.48%	15.09B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	42.02B
OTSUKA HOLDINGS CO., LTD.	+22.40%	21.66B
CIPLA LIMITED	+16.12%	14.21B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.37B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.59B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.56B
GEDEON RICHTER	+4.17%	4.64B

Generic Pharmaceuticals

Sandoz Group AG

Equities

SDZ

CH1243598427

Pharmaceuticals

SANDOZ : Raised to Buy by Berenberg

Latest news about Sandoz Group AG

Chart Sandoz Group AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sandoz Group AG

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Generic Pharmaceuticals